Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Size: px
Start display at page:

Download "Data Quality and Integrity: From Clinical Monitoring to Marketing Approval"

Transcription

1 Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November

2 Objectives Identify the importance of accuracy, completeness and validity of data collected during a clinical development program Plan for a clinical study report used for marketing approval Discuss the importance of monitors and investigational site personnel in increasing the quality of data required for marketing approval 2

3 Outline Overview Marketing application Data collection and monitoring Clinical study report (CSR) 3

4 Start at the end! Keep it simple! Maintain consistency! 4

5 Start at the end The primary goal in product development is to bring new compounds to market that can either treat previously untreatable diseases or offer improved benefits to patients, when compared to existing drugs 5

6 Start Line Hypothesis/ Study design and planned analysis Monitor s Pit Stop Investigator 1 Investigator 2 Investigator 3 Finish Line Clinical study report / Marketing Application Investigator 4 Monitor s Pit Stop 6

7 What is needed to obtain a marketing approval? Regulatory authorities thoroughly review a marketing submission to evaluate the data submitted for a product. The product has to demonstrate efficacy with acceptable safety Results and conclusions of studies -CSRs This relies on data quality and integrity Exploratory analyses on raw data Regulatory Authority audits at sites 7

8 What should be done to meet the requirements of data quality? Actions must be taken in the earliest clinical stages Sponsors are responsible for developing appropriate study designs and planned analyses 8

9 What should be done to meet the requirements of data quality? (2) Investigators, site personnel and monitors are the frontline players who ensure protocol compliance and provide clean clinical data which, in turn, will provide quality efficacy and safety analyses in CSRs that ultimately supports marketing approval 9

10 How should these actions be done? There is no universal way, since each clinical development program is unique There are universal guidelines Applicable laws Directives Guidelines ICH E6 Good Clinical Practices (GCPs) ICH E3 Structure and content of CSRs Standard operating procedures 10

11 Definition of GCPs «An international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.» 11

12 GCPs why do we need them? To protect the rights, integrity and confidentiality of subjects To ensure that all data collected and reported during the trial are credible and accurate 12

13 Principles of GCPs Data collection (1) 1. Clinical trials should be scientifically sound, and described in a clear, detailed protocol 2. Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s) 3. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification.

14 Principles of GCPs Data collection (2) 4. Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol 5. Systems with procedures that assure the quality of every aspect of the trial should be implemented.

15 Marketing application 15

16 Marketing application Nonclinical data Chemistry, manufacturing and controls (CMC) data Clinical data Overview and summaries of integrated efficacy and safety data - all clinical studies conducted with the product during the clinical development program CSRs 16

17 Marketing application (2) Labeling Defines appropriate patient population for treatment Provides adequate information to enable safe and effective use 17

18 Regulatory marketing application CTD Quality Overall Summary (2.3) 1 Regional Administrative Forms LABELING Module 2 CTD Table of Contents (2.1) CTD Introduction (2.2) Nonclinical Overview (2.4) Nonclinical Written and Tabulated Summary (2.6) Clinical Overview (2.5) Clinical Written Summary (2.7) Module 3 Module 4 Module 5 Labeling Overall Summary Detailed Summaries Tabulated Summaries Quality Nonclinical Study Reports Clinical Study Reports Reports/Data Q S E Q = Quality/Chemistry,CMC S = Safety/Nonclinical E = Efficacy/Clinical 18

19 Marketing application Clinical review (1) The role of the product in the existing treatment standard of care for the indication Efficacy data Study design Choice of endpoints, study population Choice of control, adequacy of blinding Appropriateness of statistical analyses Contribution of sponsors is crucial 19

20 Marketing application Clinical review (2) Study design Per GCPs Section 6.4: «The scientific integrity of the trial and the credibility of the data from the trial depend substantially on the trial design» The protocol design and planned analyses and ultimately case report forms (CRFs) design have important influences on data quality. Prospectively identify the critical data Simplify data collection Contribution of sponsors is crucial 20

21 Marketing application Clinical review (3) Aspects of the conduct of the study which are deemed critical to conclusions Protocol compliance Eligibility, blinding, randomization, treatment, assessments, concomitant medications Contribution of monitors and investigational site personnel is crucial 21

22 Marketing application Clinical review (4) Safety data Extent of safety testing, size of the safety database Duration of exposure Common adverse events Deaths, other serious adverse events and adverse events that led to discontinuation Narratives, listings, CRFs Contribution of sponsors, monitors and investigational site personnel is crucial 22

23 Marketing application Clinical review (5) Listings Tables Data Consistency Labeling Summaries 23

24 Marketing application Lessons learned (1) Complete case report forms are submitted for: Deaths Other serious adverse events Other significant adverse events (e.g., adverse events leading to discontinuation) Adequate completion and monitoring are important since authorities require the case report forms to be part of the submission! 24

25 Marketing application Lessons learned (2) Data uniformity Laboratory testing units For same tests, various units could be used in different countries/sites 25

26 Marketing application Lessons learned (2) Adverse events causality definitely, probably, possibly, suspected, likely etc. Be consistent and keep it simple! 26

27 Data collection and monitoring 27

28 Clinical data flow - data collection and monitoring 28

29 Purpose of monitoring Assures the integrity of data generated Assures appropriate study conduct in accordance with GCP To ensure the validity and accuracy of the data, sponsors periodically send monitors to study sites to verify that subjects are treated according to the study protocol and that the information is reported accurately. 29

30 Protocol compliance and data validity Appropriately trained investigators and site personnel are critical to ensure the protocol is followed correctly and that CRFs are properly completed Study monitors check on the progress and quality of performance of the study by reviewing CRFs and other study records to ensure that the documentation is complete 30

31 What can the sponsor do to help obtain clean data? Ensure all study documents (protocol, lab manual, CRF, etc..) are clear and contain enough detail Will minimize ambiguity on the site s end and make the execution of the study easier CRF completion guidelines Will reduce the number of queries Ensure the monitors are appropriately trained

32 What can a monitor do to obtain cleaner data? (1) Training does not end at the site initiation visit; it is done throughout the study New site personnel and every time errors/omissions are noted in the CRF Understand what needs to be captured Review tools available (e.g., CRF completion guideline, Q&A log and meeting minutes) Keep track of individual CRF entry decisions 32

33 What can a monitor do to obtain cleaner data? (2) Ensure consistency: between sites with respect to CRF entry and DCR resolution between SAE reports and AE CRF pages between the same data collected on more than one CRF page Provide instruction to site if new DCRs should be expected on-site after the site termination visit Maintain a good rapport with the study coordinator! 33

34 Data collection is conducted according to GCPs Consequences of noncompliance Suspension or cancellation of trial and seizure of investigational product Market approval of investigational product declined Prosecution under penalties defined in each country law 34

35 Data collection and monitoring Lessons learned (1) Documentation is the key for auditors to be able to reconstruct the study. Document everything! If it isn t documented it wasn t done! 35

36 Data collection and monitoring Lessons learned (2) Safety assessments AE Causality It is often the study coordinator that is entering the AE causality in the CRF and it is rarely documented in the source documents A good monitor will ensure that the investigator has been the one to do the final determination It is important to remember that it is the investigator s responsibility to assign each AE causality, not the study coordinator nor the sponsor. 36

37 Data collection and monitoring Lessons learned (3) When discussed with monitors, they all say that they became better monitors when they helped reviewing data listings and assisted authoring CSRs Look at things from a different perspective! 37

38 Clinical study report 38

39 Clinical data flow Clinical study report 39

40 Clinical study report Guidelines ICH Harmonised Tripartite Guideline E3, Structure and Content of Clinical Study Reports : Single core clinical study report acceptable to all regulatory authorities of the ICH regions Additional modules/appendices meet regional regulatory requirements 40

41 Clinical study reports Advantages of the standard format Familiarity for all reviewers Consistency for marketing application in multiple ICH regions 41

42 Clinical study report Structure Fully integrated clinical and statistical report Report body Sections 1.0 to 15.0 Appendices Section

43 Clinical study report Organization (1) Section 1.0: Title page Section 2.0: Synopsis Section 3.0: Table of contents Section 4.0: List of abbreviations, definitions of terms Section 5.0: Ethics Section 6.0: Investigators and study administrative structure Section 7.0: Introduction Section 8.0: Study objectives 43

44 Clinical study report Organization (2) Section 9.0: Investigational plan Section 10.0: Study subjects Section 11.0: Efficacy evaluation Section 12.0: Safety evaluation Section 13.0: Discussion and overall conclusions Section 14.0: Tables, figures, and graphs referred to but not included in the text Section 15.0: Reference list Section 16.0: Appendices 44

45 Clinical study report Content Provide adequate detail to allow regulatory authorities to replicate critical analyses Clear explanation of how critical study design features were chosen Clear explanation of the planned and actual methods, and conduct of the study Adequate individual subject data and details of analytical methods (data listings) 45

46 Clinical study report High quality document Complete Design, methods, conduct, deviations Summary and individual subject data Efficacy and safety evaluations and conclusions Well organized, free of ambiguity or inconsistencies Accurate representation of the clinical data 46

47 Clinical study report Tables and figures Essential results for the following should be presented and summarized in text and repeated in Section 14.0: Demographics Efficacy Safety Pharmacokinetics (if applicable) Cross reference to text, and supporting tables, figures, and data listings in Appendices. 47

48 Clinical study report Typical timelines 2 months is a reasonable period to finalize a CSR but Can be accelerated depending on sponsor needs! 48

49 Clinical study report Study specific documents (1) Final protocol and amendments Statistical analysis plan and amendments, if available CRF Investigator s Brochure Information on waivers and protocol deviations Study procedures manual, if available Central lab manuals with reference ranges Investigational product information Study s regulatory history 49

50 Clinical study report Study specific documents (2) Site visit reports Compliance Issues Adverse events Serious adverse event reports SAE reports/medwatch forms Site narratives 50

51 Clinical study report Study specific documents (3) Site correspondence related to deviations/ exceptions Inclusion / exclusion exception request Deviation request Notes to file Previous example of CSR from sponsor (if available) 51

52 Clinical study report Lessons learned (1) Do not wait for the study to finish to start the clinical study report Begin authoring as soon as the protocol and statistical analysis plan are finalized! 52

53 Clinical study report Lessons learned (2) The CSR data presentation should be based on the efficacy and safety summaries required for the marketing application If a sponsor thinks far enough ahead to plan for marketing application from the beginning, they are more likely to successfully cross the finish line! 53

54 Clinical study report Lessons learned (3) Ensure that the tables and listings have undergone a quality control review and are considered final before beginning to author the efficacy and safety evaluation sections of the CSR Otherwise you may be in for plenty of unwanted surprises and lots of re-writing! 54

55 Clinical study report Lessons learned (4) Protocol deviations Usually not in the CRF but presented in monitoring reports Determine what information is to be included and how detailed it will be Plan ahead! It is more efficient to build a tool at the planning and initiation stages than try to retrieve the information at the end when time is precious 55

56 Conclusion Obtaining high-quality data in the most efficient way is a question of team effort! Interaction and contribution Sponsors, investigational sites and regulatory authorities Processes Monitoring Auditing Tools Guidance documents Study documents Quality control plan 56

57 Start Line Hypothesis/ Study design and planned analysis Monitor s Pit Stop Investigator 1 Investigator 2 Investigator 3 Finish Line Clinical study report / Marketing Application Investigator 4 Monitor s Pit Stop 57

58 Rational study design and analyses Data standardization / simplification Sponsor Monitor Investigator/site Careful monitoring Protocol compliance Adequate completion of source documents / CRF Adequate safety reporting Well- organized and high quality CSR and marketing application Inspection preparation 58

59 Start at the end! Keep it simple! Maintain consistency! 59

60 Questions? 60

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

Ensuring Quality of Regulatory Clinical Documents

Ensuring Quality of Regulatory Clinical Documents Ensuring Quality of Regulatory Clinical Documents Henry Li *, Kim Hanna and Steve Petteway Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA Summary A large number of clinical documents

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO 23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency Conducting and reporting a GCP Inspection Gunnar Danielsson Medical Products Agency Preparation for an inspection Inspection plan Create worksheets for the inspection general project specific study specific

More information

Good Clinical Practice

Good Clinical Practice Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie

More information

Stephanie Gentilin, CCRA

Stephanie Gentilin, CCRA Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials

Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials Lisa Marie Saldanha Senior Director & Head Academic Research & Delivery Solutions Real World Insights

More information

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

Conducted Under an IND to Support a

Conducted Under an IND to Support a Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.

More information

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may

More information

Common CSR Template Mapped to ICH E3 and CORE Guidance

Common CSR Template Mapped to ICH E3 and CORE Guidance Common CSR Template Mapped to ICH E3 and CORE Guidance ICH E3 CORE Common CSR Rationale 1. TITLE PAGE 1. TITLE PAGE TITLE PAGE Per CORE, title page does not 2. SYNOPSIS 2. SYNOPSIS SYNOPSIS require a Heading

More information

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com Trial Services The allround trial specialist in cardiology Leading since 1983 cardialysis.com Trial design The key factor in achieving a successful clinical trial is to have a well-prepared, consistent

More information

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The

More information

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,

More information

Good Clinical Practice

Good Clinical Practice Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete

More information

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles

More information

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference

More information

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick

More information

Compliance and Quality Monitoring: What, Why, When, and How

Compliance and Quality Monitoring: What, Why, When, and How Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University

More information

Standard Operating Procedure

Standard Operating Procedure Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if

More information

PROTOCOL DRAFTING GUIDE

PROTOCOL DRAFTING GUIDE MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH

More information

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs

More information

Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA

Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA 1 www.fda.gov WHAT MEDICAL REVIEWERS CAN DO WITH STANDARDIZED DATA AND METADATA RECEIVED IN MODULE 5 Eileen Navarro, MD, FACP OCS/OTS/CDER/FDA

More information

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are

More information

Clinical Trials & Regulatory

Clinical Trials & Regulatory Clinical Trials & Regulatory Infrastructures t MENA Raeda Mustafa, B.Sc.Pharm., MBA, CCRA, CCRC/ Molecule CRO Updates to ICH GCP E6 (R2) and BE Studies 3rd MENA Regulatory Conference on Bioequivalence,

More information

1.0 Scope. 2.0 Abbreviations

1.0 Scope. 2.0 Abbreviations 1.0 Scope This Standard Operating Procedure (SOP) has been written in order to conduct clinical studies according to the International Conference on Harmonisation of Technical Requirements for Registration

More information

Louise Brook Clinical Trials Quality Monitor. Date

Louise Brook Clinical Trials Quality Monitor. Date Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person

More information

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by: GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional

More information

Views of a Clinical Study Report

Views of a Clinical Study Report Out-of-(CSR)-Body Experiences Tips on Assembling Appendices, Datasets, and CRFs Susan C Sisk, PhD, RAC 1 Views of a Clinical Study Report OR Photos courtesy of Leigh Vaughan and RAPS, 2008 2 Topics Process

More information

Clinical Research: A Multifaceted Discipline

Clinical Research: A Multifaceted Discipline Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

Development and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts

Development and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts Development and Implications of a Redacted Clinical Trial Protocol for Posting Online With the Published Manuscripts Namit Ghildyal, Yvette Ng, Craig Tendler, Chris H. Takimoto, Susan Glasser Janssen Research

More information

Development Safety Update Report Guidance

Development Safety Update Report Guidance Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational

More information

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010 IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized

More information

Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting

Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting Young-Hak Kim, MD, PhD Department of Medicine,, University of Ulsan College of Medicine, Seoul, Korea Responsibilities

More information

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit? Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination

More information

OCTC 2012 CRO Selection

OCTC 2012 CRO Selection OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed

More information

RESEARCH AUDIT Standard Operating Procedure

RESEARCH AUDIT Standard Operating Procedure Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor

More information

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

GUIDELINES FOR CONDUCTING CLINICAL TRIALS. GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,

More information

Document Reuse: Theory and Practice

Document Reuse: Theory and Practice Document Reuse: Theory and Practice Peggy Boe, RN Sr. Director, Medical Writing Image Solutions, Inc (ISI) Company logo here Best Practice: Single Sourcing Creating reusable text and information Requires

More information

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough

More information

ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL

ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE

More information

Source And Regulatory Documentation for DMID Clinical Studies

Source And Regulatory Documentation for DMID Clinical Studies Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in

More information

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies OFFICE FOR RESEACH PROCEDURE Sponsor Responsibilities in Investigator Initiated Studies 1. Purpose: To define Sponsor Responsibilities in the conduct of Investigator driven studies. 2. Scope: All phases

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

Inspections: an academic perspective

Inspections: an academic perspective Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk

More information

OFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out

OFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical

More information

Study Files and Filing

Study Files and Filing Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm

More information

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312

More information

Standard Operating Procedures (SOP) Research and Development Office

Standard Operating Procedures (SOP) Research and Development Office Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:

More information

Research Study Close-down and Archiving Procedures

Research Study Close-down and Archiving Procedures Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.

More information

Quality Assurance in Clinical Trials Introduction

Quality Assurance in Clinical Trials Introduction Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)

More information

GCP/Clinical Investigation in Japan

GCP/Clinical Investigation in Japan GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)

More information

Standard Operating Procedure Research Governance

Standard Operating Procedure Research Governance Research and Enterprise Standard Operating Procedure Research Governance Title: Development, Review and Amendment: Study Protocol SOP Reference Number: QUB-ADRE-002 Date prepared 28 May 2008 Version Number:

More information

Clinical trials from CRA s point of view

Clinical trials from CRA s point of view Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical

More information

PhUSE Paper PP07. EPOCH in Reverse. Ann Croft, LEO Pharma, Hurley, UK

PhUSE Paper PP07. EPOCH in Reverse. Ann Croft, LEO Pharma, Hurley, UK Paper PP07 EPOCH in Reverse Ann Croft, LEO Pharma, Hurley, UK ABSTRACT After supplying test data through the electronic gateway to the FDA, LEO Pharma was informed that the FDA required some updates to

More information

Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary

Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary Standard Operating Procedures for Clinical Research Personnel Part 16 Wendy Bohaychuk and Graham Ball GCRP Consultants, Lakehurst General Delivery, Ontario, Canada KOL 2JO Summary This is the 16th in a

More information

Simplifying Clinical Trials

Simplifying Clinical Trials Simplifying Clinical Trials A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. A division of Phoenix Progressive Certifications Enterprise Pvt. Ltd. Company Overview : PPCE is an efficient

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia "From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS

More information

CHAPTER 3 DRUG DEVELOPMENT. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT TO APPROVAL

CHAPTER 3 DRUG DEVELOPMENT. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT TO APPROVAL CHAPTER 3 DRUG DEVELOPMENT indications, which are clearly different from those of drugs, which have already been approved for manufacture and marketing. 1.1 Development of New Drugs 1. PROCESS FROM DEVELOPMENT

More information

Clinical Trial Basics:

Clinical Trial Basics: Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial

More information

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational

More information

Conducting Clinical Trials of Investigational Medicinal Products

Conducting Clinical Trials of Investigational Medicinal Products Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures

More information

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE www.gratanet.com Among other regulations aimed at the implementation of the Agreement

More information

Standard Operating Procedure for Archiving

Standard Operating Procedure for Archiving Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member

More information

GUIDELINE FOR GOOD CLINICAL PRACTICE TABLE OF CONTENTS

GUIDELINE FOR GOOD CLINICAL PRACTICE TABLE OF CONTENTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE i GUIDELINE FOR GOOD CLINICAL PRACTICE ICH Harmonised Tripartite Guideline Having reached

More information

An Introduction to Clinical Research and Development

An Introduction to Clinical Research and Development Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is

More information

ICH/GCP Guidelines Self-Evaluation Questionnaire

ICH/GCP Guidelines Self-Evaluation Questionnaire THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees

More information

1 The Clinical Research Coordinator (CRC)... 1

1 The Clinical Research Coordinator (CRC)... 1 TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...

More information

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information

More information

Investigator Site File Index (Medical Devices)

Investigator Site File Index (Medical Devices) Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note

More information

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage

More information

Developing and Implementing a Comprehensive Clinical QA Audit Program

Developing and Implementing a Comprehensive Clinical QA Audit Program Developing and Implementing a Comprehensive Clinical QA Audit Program Henry Li 1, *, Susan Hawlk 2, Kim Hanna 1, Gerald Klein 1 and Steve Petteway Jr. 1 1 Talecris Biotherapeutics, 79 T. W. Alexander Drive,

More information

Author Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document

Author Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document MELBOURNE CHILDREN S TRIALS CENTRE (MCTC) Guideline document title: Developing, amending and complying with research protocols Version: 2.0 Author: Melbourne Children s Trials Centre (MCTC) Author Signature:

More information

Welcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site,

Welcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site, Welcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site, on-site, and central monitoring, and finally, considering

More information

Investigator s Responsibility

Investigator s Responsibility Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment

More information

Trial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.

Trial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links. Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update

More information

Learning about Clinical Trials

Learning about Clinical Trials Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the

More information

Implementing Good Clinical Practice at an Academic Research Institution

Implementing Good Clinical Practice at an Academic Research Institution Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time

More information

QUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW???

QUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW??? L.Massad GCP an International Ethical and Scientific quality standard by which clinical trials are designed, implemented and reported so that there is public assurance that the data are credible and the

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

Vaccine Prequalification Dossier

Vaccine Prequalification Dossier Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)

More information

June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB

June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits

More information

Clinical Trials application process, legislation & guidelines

Clinical Trials application process, legislation & guidelines Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission

More information

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify

More information